The approval of medicines called second-generation antipsychotics has allowed bipolar I and some conditions that come with it to be treated. A person who has bipolar I disorder can go through various ...

Credit: Thinkstock. Abilify Asimtufii is intended for dosing every 2 months via intramuscular injection in the gluteal muscle. The Food and Drug Administration (FDA) has approved Abilify Asimtufii ® ...

Abilify Asimtufii (aripiprazole) is prescribed to help treat schizophrenia and bipolar I disorder. The drug comes as a suspension (a liquid mixture) that a healthcare professional injects into a ...

Abilify Asimtufii, the bipolar I disorder treatment from Otsuka and Lundbeck, has entered the world of CGI animation as part of a multichannel direct-to-consumer (DTC) campaign. The two drugmakers ...

Abilify (aripiprazole) is a prescription atypical (second-generation) antipsychotic that treats depression, schizophrenia, and bipolar disorder. It also treats irritability related to autism and ...

Dosage for Abilify (aripiprazole) may vary based on the condition it’s being used to treat. Your doctor may adjust your dosing of Abilify over the course of your treatment. The active ingredient in ...

Aripiprazole is a generic prescription medication that’s prescribed for certain mental health conditions. Aripiprazole belongs to a class of drugs a called atypical antipsychotics. A class of drugs is ...

NEW YORK, April 6 (Reuters) - Bristol-Myers Squibb Co said on Monday it will sell its Abilify schizophrenia drug more than two years longer than expected, helping to shore up profits after the company ...

Bristol-Myers Squibb Co. will pay $19.5 million to settle allegations that the London-based drugmaker improperly marketed and promoted its anti-psychotic drug Abilify, reports Reuters. The drugmaker ...

Otsuka Pharmaceuticals and Proteus Digital Health’s sensor-carrying pill Abilify MyCite is on its way to US patients thanks to a new collaboration agreement between Otsuka and Magellan Health.

Bristol-Myers Squibb Co and Otsuka Pharmaceutical Co have reached a global settlement with plaintiffs who sued the companies alleging they failed to warn their antipsychotic drug Abilify could cause ...